Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Wire Syria.
Press releases published on September 16, 2025
KFSHRC réduit de 75 % le temps d’attente aux urgences pour obtenir une hospitalisation
RIYAD, Arabie saoudite, 16 sept. 2025 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre (KFSHRC) à Riyad a réduit le temps d’attente médian aux urgences, qui est passé de plus de 13 heures en 2023 à seulement 3,2 heures au milieu …
HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development
Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of solid tumors Discovery of unique combination of cytokines in multi-functional fusion protein molecule that exhibits …
SpyGlass Pharma Appoints Anand Sundaram as Head of Commercial
ALISO VIEJO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a late-stage biopharmaceutical company, today announced the appointment of Anand Sundaram as the company’s Vice President, Head of Commercial. Mr. Sundaram brings over a decade of …
Hyperion DeFi Enters Into First HAUS Agreement With Proprietary Trading Firm Credo
LAGUNA HILLS, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid’s native token, HYPE, today …
Medicines360 acquires global rights to PeriPeach™, advancing new maternal health technology through the 360 Innovation Hub™
SAN FRANCISCO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Medicines360, a women’s health innovation organization with a mission to be a catalyst for change, today announced that it has acquired global licensing rights to PeriPeach, an investigational medical …
Starton Therapeutics Granted New U.S. Patent #12,390,457 Titled “Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use” a Formulation of STAR-LLD
New U.S. patent provides IP coverage for the formulation to 2042 Further expands Starton’s intellectual property portfolio surrounding its lead product candidate, STAR-LLD, Method of Use Patent #11,197,852 which provides IP coverage to 2040 PARAMUS, N.J., …
Parexel Announces Appointment of Rob Goodwin as Chief Operating Officer
RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry, today announced the appointment of Rob …
Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding
A Media Snippet accompanying this announcement is available by clicking on this link. DUBLIN, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The American Academy of Sleep Medicine Foundation (AASM Foundation) and Avadel Pharmaceuticals are celebrating five years of …
FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025 Second Fast Track designation granted by FDA for CRB-701 NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“ …
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
MADRID and CAMBRIDGE, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it continues to expand its patent …
Marine Biologics Partners with Molecular Quantum Solutions to Accelerate Next-Generation Biomaterials Development
BERKELEY, Calif. and COPENHAGEN, Denmark, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biomaterials company Marine Biologics today announced an exclusive strategic partnership with Molecular Quantum Solutions (MQS) in which Marine Biologics will be the sole …
Highridge Medical Enters Exclusive Distribution Agreement for the PathKeeper Surgical Navigation System
WESTMINSTER, Colo., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Highridge Medical, one of the world’s largest privately held spine companies with an innovative and clinically supported portfolio, announced today it has entered into an exclusive distribution …
MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
LA JOLLA, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract …
Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation
- Findings highlight the potential of antibiotic-eluting bioenvelopes to transform cardiac implantable electronic device (CIED) pocket management - GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company …
Izotropic Publishes New FAQ Page for Investors, Analysts, and Healthcare Decision-Makers
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging …
Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old
First data on treatment of NPC1 with Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) in this age group over a period of 48 weeks At 48 weeks of the sub-study, 7 of 9 patients1 showed stabilization or improvement in CGI-S score Data presented at the15th …
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
GLEN ALLEN, Va., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related …
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis. Under the terms of the amended agreement, Exelixis will …
Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) today announced the Company is in the process of addressing comments received by the U.S. Food and Drug Administration (FDA) in connection with the …
Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)
-- Upsized Series A Financing Brings Total Amount Raised to $133 Million -- -- GAD Affects 3.1% of U.S. Adult Population; Minority of Patients Receive Treatment -- -- Reunion Expects to Initiate RECLAIM Phase 2 Trial Evaluating RE104 for GAD in 1Q 2026 -- …